← Product Code [LLH](/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH) · K082499

# C. DIFF QUIK CHEK COMPLETE (K082499)

_Techlab, Inc. · LLH · Mar 26, 2009 · Microbiology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH/K082499

## Device Facts

- **Applicant:** Techlab, Inc.
- **Product Code:** [LLH](/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH.md)
- **Decision Date:** Mar 26, 2009
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.2660
- **Device Class:** Class 1
- **Review Panel:** Microbiology
- **Attributes:** Pediatric

## Indications for Use

The C. DIFF QUIK CHEK COMPLETE™ test is a rapid membrane enzyme immunoassay for the simultaneous detection of C. difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. The test detects C. difficile antigen, glutamate dehydrogenase, as a screen for the presence of C. difficile and confirms the presence the toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease. The test is to be used as an aid in the diagnosis of C. difficile disease. As with other C. difficile tests, results should be considered in conjunction with the patient history.

## Device Story

Rapid membrane enzyme immunoassay for simultaneous detection of C. difficile glutamate dehydrogenase (GDH) antigen and toxins A and B in fecal specimens. Device utilizes antibodies specific for GDH and toxins A/B immobilized on a reaction window membrane. Fecal specimen is diluted and mixed with antibody-horseradish peroxidase conjugate; mixture is added to sample well. During 15-minute incubation, GDH/toxin in sample binds to conjugate; complexes migrate to membrane and are captured by immobilized antibodies. After wash, substrate is added; 10-minute incubation produces blue lines indicating positive results. Visual examination by healthcare provider. Positive antigen line screens for C. difficile; positive toxin line confirms toxigenic C. difficile. Results aid clinical diagnosis in conjunction with patient history.

## Clinical Evidence

Clinical study included 1126 fecal samples from patients aged 5 months to 100 years. Antigen detection compared to bacterial culture showed 90.5% sensitivity and 93.1% specificity. Toxin A/B detection compared to tissue culture assay showed 87.8% sensitivity and 99.4% specificity. Reproducibility studies across 3 sites over 5 days showed consistent performance.

## Technological Characteristics

Rapid membrane enzyme immunoassay; utilizes immobilized antibodies against C. difficile GDH and toxins A/B; horseradish peroxidase-conjugated antibodies; visual readout via blue line formation; manual test format; no instrumentation required.

## Regulatory Identification

A microorganism differentiation and identification device is a device intended for medical purposes that consists of one or more components, such as differential culture media, biochemical reagents, and paper discs or paper strips impregnated with test reagents, that are usually contained in individual compartments and used to differentiate and identify selected microorganisms. The device aids in the diagnosis of disease.

## Predicate Devices

- C. DIFF QUIK CHEK ([K053572](/device/K053572.md))
- TOX A/B QUIK CHEK ([K050891](/device/K050891.md))
- C. DIFF CHEK-60 ([K030992](/device/K030992.md))
- C. DIFFICILE TOX A/B II ([K003306](/device/K003306.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE

A. 510(k) Number:
K082499

B. Purpose for Submission:
Substantial equivalence determination for a new toxin A and B and antigen combined as one test system

C. Measurand:
Clostridium difficile (C. diff) toxins A and B and the antigen glutamate dehydrogenase (GDH)

D. Type of Test:
A qualitative rapid immunoassay

E. Applicant:
Techlab, Inc.

F. Proprietary and Established Names:
C. DIFF QUIK CHEK COMPLETE™

G. Regulatory Information:
1. Regulation section:
866.2660
2. Classification:
Class I
3. Product code:
LLH – Reagents, Clostridium difficile toxin

{1}

MCB- Antigen, Clostridium difficile

4. Panel:
83- Microbiology

H. Intended Use:

1. Intended use(s):

The C. DIFF QUIK CHEK COMPLETE™ test is a rapid membrane enzyme immunoassay for the simultaneous detection of C. difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. The test detects C. difficile antigen, glutamate dehydrogenase, as a screen for the presence of C. difficile and confirms the presence of toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease. The test is to be used as an aid in the diagnosis of C. difficile disease. As with other C. difficile tests, results should be considered in conjunction with the patient history.

2. Indication(s) for use:

The C. DIFF QUIK CHEK COMPLETE™ test is a rapid membrane enzyme immunoassay for the simultaneous detection of C. difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. The test detects C. difficile antigen, glutamate dehydrogenase, as a screen for the presence of C. difficile and confirms the presence of toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease. The test is to be used as an aid in the diagnosis of C. difficile disease. As with other C. difficile tests, results should be considered in conjunction with the patient history.

3. Special condition for use statement(s):

For prescription use only

4. Special instrument requirements:

Not applicable.

I. Device Description:

The C. DIFF QUIK CHEK COMPLETE™ test uses antibodies specific for glutamate dehydrogenase and toxins A and B of C. difficile. The device contains a Reaction Window with three vertical lines of immobilized antibodies. The antigen test line ("Ag") contains antibodies against C. difficile glutamate dehydrogenase. The control line ("C") is a dotted line that contains anti-horseradish peroxidase (HRP) antibodies. The toxin A and B test line ("Tox") contains antibodies against C. difficile toxins A and B. The

{2}

Conjugate consists of antibodies to glutamate dehydrogenase and antibodies to toxins A and B coupled to horseradish peroxidase.

## J. Substantial Equivalence Information:

1. Predicate device name(s):
There are four predicate device referenced to be substantially equivalent to the C. DIFF QUIK CHEK COMPLETE™.
- C. DIFF QUIK CHEK
- TOX A/B QUIK CHEK
- C. DIFF CHEK-60
- C. DIFFICILE TOX A/B II

2. Predicate 510(k) number(s):
- K053572
- K050891
- K030992
- K003306

3. Comparison with predicate:

|  Similarities  |   |   |   |   |   |
| --- | --- | --- | --- | --- | --- |
|  Item | C. DIFF QUIK CHEK COMPLETE™ | C. DIFF QUIK CHEK® | TOX A/B QUIK CHEK® | C. DIFF CHEK™ - 60 | C. DIFFICILE TOX A/B II™  |
|  Intended Use | Detection of C. difficile toxins A and B and GDH | Detection of C. difficile GDH | Detection of C. difficile toxins A and B | Detection of C. difficile GDH | Detection of C. difficile toxins A and B  |
|  Specimen Types | Human Fecal Specimens | Human Fecal Specimens | Human Fecal Specimens | Human Fecal Specimens | Human Fecal Specimens  |
|  Technologies | Enzyme Immunoassay - Rapid Membrane | Enzyme Immunoassay - Rapid Membrane | Enzyme Immunoassay - Rapid Membrane | Enzyme Immunoassay - Microassay Plate | Enzyme Immunoassay - Microassay Plate  |

{3}

|  Differences  |   |   |   |   |   |
| --- | --- | --- | --- | --- | --- |
|  Item | C. DIFF QUIK CHEK COMPLETE™ | C. DIFF QUIK CHEK® | TOX A/B QUIK CHEK® | C. DIFF CHEK™ - 60 | C. DIFFICILE TOX A/B II™  |
|  Limit of Detection (Analytical Sensitivity) | Toxin A ≥ 0.63 ng/mL
Toxin B ≥ 0.16 ng/mL
GDH ≥ 0.8 ng/mL | GDH ≥ 0.8 ng/mL | Toxin A ≥ 0.63 ng/mL
Toxin B ≥ 1.25 ng/mL | GDH ≥ 0.8 ng/mL | Toxin A ≥ 0.8 ng/mL
Toxin B ≥ 2.5 ng/mL  |
|  Clinical Sensitivity | Toxins A&B: 87.8%
GDH: 90.5% | GDH: 92.8% | Toxins A&B: 90.2% | GDH: 70.5% | Toxins A&B: 92.2%  |
|  Clinical Specificity | Toxins A&B: 99.4%
GDH: 93.1% | GDH: 92.6% | Toxins A&B: 99.7% | GDH: 91.2% | Toxins A&B: 100%  |

## K. Standard/Guidance Document Referenced (if applicable):

This 510(k) Premarket Notification was prepared and referenced the following guidance document and recognized standard:

- “Review Criteria for Devices assisting in the diagnosis of C. difficile associated disease” May 1990, ODE/CDRH Guidance Document.
- User Protocol for Evaluation of Qualitative Test Performance, Clinical Laboratory Standards Institute (CLSI) Approved Guideline, EP12-A (August 2002)

## L. Test Principle:

The device contains a Reaction Window with two vertical lines of immobilized antibodies and center dots of immobilized antibody. One line consists of antibodies against C. difficile glutamate dehydrogenase and the second line contains antibodies against C. difficile toxins A and B. After the incubation period, "Ag" reaction is examined visually for the appearance of a vertical blue line on the "Ag" side of the Reaction Window. A blue line indicates a positive test. If the "Ag" is positive, then the "Tox" reaction should be examined visually for the appearance of a blue line on the "Tox" side of the Reaction Window. A blue line indicates a positive test. A positive "C" reaction, indicated by a vertical dotted blue line under the "C" portion of the Reaction Window, confirms that the test is working properly and the results are valid.

## M. Performance Characteristics (if/when applicable):

1. Analytical performance:

{4}

# a. Precision/Reproducibility:

The reproducibility of the C. DIFF QUIK CHEK COMPLETE™ test was determined using 12 fecal specimens that were coded to prevent their identification during testing. Testing was performed at 3 independent laboratories, which tested the samples for 3 days. The samples produced the expected results  $100\%$  of the time.

An additional 5-day study was performed at 3 sites by running a set of low positive, moderate positive and high negative fecal samples that were spiked with glutamate dehydrogenase, Toxin A and Toxin B. The samples were run in triplicate, twice a day over a 5-day period by multiple technicians at each site. The combined antigen and toxin data from the 5-day reproducibility study is shown in Table 7. The antigen data for Sample 1 was below  $90\%$  negative at one site and was consistently negative for antigen at the other two sites. The toxin data for Sample A was below  $90\%$  positive at one site, and was consistently positive for toxin at the other two sites. No single site reported results below expectations for both antigen and toxin.

Table 7 Summary of 5-day reproducibility study

|  Sample ID | Antigen Positive | Antigen Negative | Toxin Positive | Toxin Negative  |
| --- | --- | --- | --- | --- |
|  Sample 1 (95% negative results expected) | 15 (16.7%) | 75 (83.3%) | 0 (0%) | 90 (100%)  |
|  Sample A (95% positive results expected) | 89 (98.9%) | 1 (1.1%) | 65 (72.2%) | 25 (27.8%)  |
|  Sample B (mod positive) | 87 (96.7%) | 3 (3.3%) | 86 (95.5%) | 4 (4.5%)  |

The Reproducibility study was satisfactory for this type of assay.

# b. Linearity/assay reportable range:

Not applicable.

# c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Not applicable.

# d. Detection limit:

The cutoff for GDH was determined using highly purified recombinant C. difficile glutamate dehydrogenase (rGDH). The cutoff was determined by testing dilutions of purified rGDH in diluent, in replicates of 20. The Limit of Detection (LOD) was established at  $0.20\mathrm{ng / mL}$ . The LOD for Toxin A and B GDH was determined using highly purified C. difficile Toxin A and B. The LOD for each toxin was determined by testing dilutions of purified Toxin A and B in diluent, in replicates of 20. The LOD was established at  $0.45\mathrm{ng / mL}$  for Toxin A and  $0.06\mathrm{ng / mL}$  for Toxin B.

{5}

The methodologies above supports the product claims for the cutoff for Toxin A at 0.63 ng/mL, 0.16 ng/mL for Toxin B and 0.8 ng/mL for GDH.

The Limit of Detection and Cutoff studies were satisfactory for this type of assay.

e. Analytical specificity: CROSS REACTIVITY

Fecal specimens inoculated with the following microorganisms to a final concentration of approximately 10⁸ or higher organisms per mL did not react in the antigen or toxin portion of the C. DIFF QUIK CHEK COMPLETE™ test:

**Bacterium or Pathogen:** Aeromonas hydrophila, Bacillus cereus, Bacillus subtilis, Bacteroides fragilis, Campylobacter coli, Campylobacter fetus, Campylobacter jejuni, Candida albicans, Clostridium butyricum, Clostridium clostridiforme, Clostridium haemolyticum, Clostridium histolyticum, Clostridium novyi, Clostridium perfringens, Clostridium septicum, Clostridium sordellii (nontoxigenic), Clostridium sporogenes, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli EIEC, Escherichia coli, Escherichia coli O157:H7, Escherichia coli ETEC, Klebsiella pneumoniae, Peptostreptococcus anaerobius, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhimurium, Serratia liquifaciens, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus aureus (Cowans), Staphylococcus epidermidis, Vibrio cholerae, Vibrio parahaemolyticus, Yersinia enterocolitica

The non-C. difficile organism, Clostridium bifermentans, reacted in the antigen portion of the C. DIFF QUIK CHEK COMPLETE™ test. The non-C. difficile organism, Clostridium sordellii, reacted in the toxin portion of the C. DIFF QUIK CHEK COMPLETE™ test was VPI 9048. This strain produces toxins HT and LT, which are homologous to toxins A and B, respectively. Appropriate recommendations will be made in the product insert, Limitations of the Procedure section to reflect this cross-reactivity.

The following viruses of 10³.³ to 10⁸.²⁵ TCID units per 0.2 mL did not react in the C. DIFF QUIK CHEK COMPLETE™ test:

**Viruses:** Adenovirus types 1, 2, 3, 5, 40, 41, Human coronavirus, Coxsackievirus B2, B3, B4, B5, Echovirus 9, 11, 18, 22, 33, Enterovirus type 68, 69, 70, 71, Rotavirus.

INTERFERING SUBSTANCES

The following substances had no effect on test results when present in feces in the concentrations indicated: mucin (3.5% w/v), human blood (40% v/v), barium sulfate (5% w/v), Imodium® (5% v/v), Kaopectate® (5% v/v), Pepto-Bismol® (5% v/v), steric/palmitic acid (40% w/v), Metronidazole (0.25% w/v), Vancomycin (0.25% w/v).

{6}

f. Assay cut-off:

The assay cutoff was determined to be at a concentration of  $0.63\mathrm{ng / mL}$  for toxin A,  $0.16\mathrm{ng / mL}$  for toxin B, and  $0.8\mathrm{ng / mL}$  for glutamate dehydrogenase. This fulfils the requirements of demonstrating a cutoff for the C. DIFF QUIK CHEK COMPLETE™.

2. Comparison studies:

a. Method comparison with predicate device:

Not applicable.

b. Matrix comparison:

Not applicable.

3. Clinical studies:

a. Clinical Sensitivity:

Clinical studies were conducted at three external sites in Pennsylvania, Ohio and Virginia using the C. DIFF QUIK CHEK COMPLETE™. Clinical truth was determined at Techlab, Inc. by testing samples using the tissue culture assay for analysis of the toxins A and B portion of the test and bacterial culture for analysis of the GDH antigen portion of the test. A total of 1126 fecal samples were collected and tested in the study. The study subjects ranged in age from 5 months-100 years, and  $60.1\%$  were female.

The antigen portion of the C. DIFF QUIK CHEK COMPLETE™ test was compared to bacterial culture. Specimens included in the evaluation were submitted to the clinical laboratories for routine testing. The bacterial culture test was performed according to in-house procedures. The results are shown in Table 1.

Table 1. Summary of clinical performance comparing C. DIFF QUIK CHEK COMPLETE  ${}^{\mathrm{{TM}}}$  test to bacterial culture

|  N = 1126 | Bacterial Culture Positive | Bacterial Culture Negative  |
| --- | --- | --- |
|  C. DIFF QUIK CHEK COMPLETE™ Antigen Line Positive | 201 | 62  |
|  C. DIFF QUIK CHEK COMPLETE™ Antigen Line Negative | 21 | 842  |
|   |   | 95% Confidence Limits  |
| --- | --- | --- |
|  Sensitivity | 90.5% | 85.7 – 93.9  |
|  Specificity | 93.1% | 91.2 – 94.7  |
|  Predictive Positive Value | 76.4% | 70.7 – 81.3  |
|  Predictive Negative Value | 97.6% | 96.2 – 98.4  |
|  Correlation | 92.6% | 91.8 – 93.4  |

{7}

The antigen portion of the C. DIFF QUIK CHEK COMPLETE™ test was compared to the tissue culture assay for the detection of C. difficile toxin. Specimens included in the evaluation were submitted to the clinical laboratories for routine testing. The results are shown in Table 2. The antigen portion of the C. DIFF QUIK CHEK COMPLETE™ test detected 98.7% of the tissue culture-positive samples.

Table 2. Summary of clinical performance comparing C. DIFF QUIK CHEK COMPLETE™ test to the tissue culture assay

|  N = 1126 | Tissue Culture Positive | Tissue Culture Negative  |
| --- | --- | --- |
|  C. DIFF QUIK CHEK COMPLETE™
Antigen Line Positive | 154 | 109  |
|  C. DIFF QUIK CHEK COMPLETE™
Antigen Line Negative | 2 | 861  |

Clinical evaluation of the toxin portion of the C. DIFF QUIK CHEK COMPLETE™ test

The toxin portion of the C. DIFF QUIK CHEK COMPLETE™ test was compared to the tissue culture assay at two clinical laboratories and in-house at TECHLAB®, Inc. Specimens included in the evaluation were submitted to the clinical laboratories for routine testing. The results are shown in Table 3.

Table 3. Summary of clinical performance comparing C. DIFF QUIK CHEK COMPLETE™ test to the tissue culture assay

|  n = 1126 | Tissue Culture Positive | Tissue Culture Negative  |
| --- | --- | --- |
|  C. DIFF QUIK CHEK COMPLETE™
Toxin Line Positive | 137 | 6  |
|  C. DIFF QUIK CHEK COMPLETE™
Toxin Line Negative | 19 | 964  |
|   |  | 95% Confidence Limits  |
| --- | --- | --- |
|  Sensitivity | 87.8% | 81.4 - 92.3  |
|  Specificity | 99.4% | 98.6 - 99.7  |
|  Predictive Positive Value | 95.8% | 90.7 - 98.3  |
|  Predictive Negative Value | 98.1% | 96.9 - 98.8  |
|  Correlation | 97.8% | 97.6 - 98.0  |

b. Clinical specificity:

See section M.3.a

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

4. Clinical cut-off:

{8}

The cutoff for the assay was established at concentrations of 0.63 ng/mL for toxin A, 0.16 ng/mL for toxin B, and 0.8 ng/mL for glutamate dehydrogenase.

5. Expected values/Reference range:

The reported incidence of *C. difficile* disease in patients with antibiotic-associated diarrhea may range from 5 to 20%, and hospitals may experience rates lower or higher than this range. It is important to consider any test results in conjunction with clinical symptoms because some healthy adults and large numbers of healthy infants (up to 50%) will be positive for *C. difficile* toxin. In addition, *C. difficile* carriage rates of 22% to 32% have been reported in cystic fibrosis patients (1,3). In the studies conducted for this device, using symptomatic patients, the incidence of toxins A and B was 12% and GDH was 18%. A positive result in the antigen portion of the *C. DIFF QUIK CHEK COMPLETE™* test confirms the presence of *C. difficile* in a fecal specimen; a negative result indicates the absence of the organism. A positive result in the toxin portion of the *C. DIFF QUIK CHEK COMPLETE™* confirms the presence of *C. difficile* toxin in a fecal specimen; a negative result indicates the absence of toxin or insufficient levels of toxin for detection.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The information submitted in this premarket notification is complete and supports a substantial equivalent decision.

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH/K082499](https://fda.innolitics.com/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH/K082499)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com